GW Pharmaceuticals announced that Sativex®, its treatment for spasticity in Multiple Sclerosis, has today been rescheduled in the UK from Schedule 1 under the Misuse of Drugs Act to Schedule 4, part 1. The move follows a recommendation to the Home Office by the Advisory Council on Misuse of Drugs (ACMD), which determined that Sativex® has a low potential for abuse and low risk of diversion. This means that Sativex®, can be prescribed in the UK with no restriction on supply, recording, storage or destruction.
Leave a Reply
You must be logged in to post a comment.